TIDMIXI

IXICO plc

26 August 2020

IXICO plc

("IXICO" or the "Company")

Investor presentation

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that a recording of the online Company presentation, delivered by Giulio Cerroni, Chief Executive Officer, and Grant Nash, Chief Finance Officer, on Tuesday 25 August, surrounding the Company's recent trading update, is now available to watch back on the Investor Meet Company platform. The Q&A has also been published following the meeting.

Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link, which will take you to the recording of the presentation and the Q&A: https://www.investormeetcompany.com/ixico-plc/register-investor

No new price-sensitive information is disclosed as part of the presentation.

For further information please contact:

 
  IXICO plc                                                            +44 (0)20 3763 7498 
  Giulio Cerroni, Chief Executive 
   Officer 
   Grant Nash, Chief Financial Officer 
 
  Cenkos Securities PLC (Nominated adviser 
   and sole broker)                                                    +44 (0)20 7397 8900 
  Giles Balleny / Max Gould (Corporate 
   Finance) 
  Michael F Johnson / Russell Kerr 
   (Sales) 
 
  Walbrook PR Ltd                               Tel: 020 7933 8780 or IXICO@walbrookpr.com 
  Paul McManus / Lianne Cawthorne                     Mob: 07980 541 893 / 07584 391 303 / 
   / 
  Alice Woodings                                                             07407 804 654 
 
 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.

END

NRAPFMMTMTITBLM

(END) Dow Jones Newswires

August 26, 2020 06:55 ET (10:55 GMT)